Articles tagged with: Daratumumab


[ by | May 30, 2015 8:02 am | 2 Comments ]
Daratumumab Continues To Show Substantial Promise As Potential New Treatment For Multiple Myeloma (ASCO 2015)

Updated results of a key Phase 1/2 trial testing the potential new myeloma therapy daratumumab were released this morning. The new results confirm previous research indicating that single-agent daratumumab has notable activity as a multiple myeloma therapy.

Specifically, the results show that nearly one third of the trial participants – who had received a median of five prior therapies – responded to single-agent daratumumab. The median time to disease progression was 3.7 months, and the estimated one-year overall survival rate was 65 percent.

Daratumumab’s safety profile in the …

Read the full story »


[ by | May 29, 2015 11:52 pm | 2 Comments ]
Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2015)

The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier today, May 29, and will go through June 2 in Chicago.

Approximately 30,000 physicians and researchers from all over the world are expected to attend the five-day meeting to discuss current research in cancer treat­ment and care.

During the meeting, there will be pre­sen­ta­tions about all types of cancer, in­clud­ing many pre­sen­ta­tions focused specifically on multiple myeloma. In fact, more than 90 myeloma-related studies are scheduled to be pre­sented, in one form or another, in connection …

Read the full story »

News, Opinion»

[ by | Jan 30, 2015 3:07 pm | 4 Comments ]
The Myeloma Quiz – January 2015

A new year is upon us.  I hope it has started well for everybody, and that all had a great holiday season!

The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the Inter­na­tional Myeloma Working Group (IMWG). In addition, the 56th annual meeting of the American Society of Hematology (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster pre­sen­ta­tions.

Therefore, it …

Read the full story »


[ by | Dec 10, 2014 3:12 pm | 3 Comments ]
ASH 2014 Multiple Myeloma Update - Day Two: Education Session And Midday Oral Session

This past Sunday was the second day of the American Society of Hema­tology’s (ASH) annual meeting, which was held in San Francisco.

As on the first day of the meeting, myeloma-related pre­sen­ta­tions once again took place during several sessions throughout the day.

A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.

While the education session was being held, a separate “scientific sym­po­sium” with two oral pre­sen­ta­tions took place in parallel.  The session focused on a novel immunotherapeutic approach to treating cancer …

Read the full story »


[ by | Dec 5, 2014 7:41 am | 4 Comments ]
ASH 2014 Preview: New Multiple Myeloma Treatments On The Horizon

The 2014 annual meeting of the American Society of Hematology (ASH) starts tomorrow, December 5, in San Francisco, and will continue until next Tuesday.

The ASH annual meeting is one of several large medical conferences where myeloma-related research findings are presented each year.  However, from a multiple myeloma perspective, the ASH meeting is generally the most important of the meetings.

At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place.  The presentations will summarize current research on a wide range of topics, including the biology of …

Read the full story »